Type 1 Diabetes Mellitus With HypoglycemiaSUPPORTNCT04233138
SUPPORT Online Training Platform for Type 1 Diabetes Self-management Education and Support (SUPPORT)
A study testing SUPPORT online platform for people with type 1 diabetes in people with Type 1 Diabetes Mellitus With Hypoglycemia, run by McGill University at 1 site in Canada.
Trial summary
There are evidences that some healthcare teams are not proposing new therapeutic and technology options that have the potential to reduce hypoglycemia for people with type 1 diabetes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Type 1 Diabetes Mellitus With Hypoglycemia
- What is being tested?
- SUPPORT online platform for people with type 1 diabetes
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 285 participants
- Where
- 1 siteCanada
- Study dates
- 5 Feb 2020to 19 Sep 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ≥ 18 years old
- Completed phase 2 of the BETTER registry
- Self-reported diagnosis of type 1 diabetes for ≥ 1 year
- Daily use of ≥ 4 injections of insulin or CSII
- Have access to Internet
- Use of an active email address
- Comprehension of English or French
Who cannot join
- Ongoing pregnancy
- Other illnesses limiting diabetes care or access to the platform (e.g. dementia and blindness)
Trial locations and contacts
1 site in 1 country.
Canada1 site
Institut de recherches cliniques de Montréal
Montreal, Quebec, H2W1R7
About this study
Official title: Optimizing Therapies and Technologies to Reduce Hypoglycemia in Type 1 Diabetes Through the SUPPORT Online Platform for Self-management Education and Support
There are evidences that some healthcare teams are not proposing new therapeutic and technology options that have the potential to reduce hypoglycemia for people with type 1 diabetes. In practice, people living with type 1 diabetes report receiving education related to insulin pumps usage mainly on key functions (how the device works) at initiation and not enough about proactive adjustments (how to optimally use the device) especially on the long-term. In brief, short-term education is technical and product-specific, rather than being based on patients' needs.There is a need to test the efficacy of different programs that may be more suited to patients' needs and desires while offering the opportunity to reduce costs (e.g. web based). Since there is a lack of expertise related to optimal use of new technologies and therapies for people living with type 1 diabetes, we propose to design and test a web-based training (e.g. courses including videos and quizzes) and support (e.g. discussion forum) platform. This will be tested through a registry-based trial.
The overall purpose of this study is to evaluate, among a group of adults living with type 1 diabetes, the SUPPORT online education platform in terms of users' satisfaction, engagement and efficacy to change the fear and the frequency of hypoglycemia.
Read the detailed description
Design and development of the SUPPORT platform:
The SUPPORT platform was designed based on the Behavior change wheel framework. The research team identified the main barriers in achieving adequate blood glucose management and in the use of an online training platform; then, features (downloadable PDFs, videos, quizzes, etc.) were designed to overcome these barriers. These training modules were developed by a team including two dietitians/certified diabetes educator, a nurse, a psychologist and endocrinologist (all specialized in type 1 diabetes). The content was then reviewed by the committee of patient-partners and clinicians working in type 1 diabetes (one endocrinologist, two residents in endocrinology, two dietitians (1 being a certified diabetes educator) and two nurses (1 being a certified diabetes educator).
Recruitment and intervention:
Recruitment of people with type 1 diabetes will be done via an email sent to the participants who completed phase 2 of the BETTER registry, are 18 years old or older, and agreed to be contacted for other studies. All participants accepting to participate will receive the full intervention for 6 months (access to the platform with bi-weekly newsletters). During the following 6 months, participants will still have access to the platform, but no newsletter will be sent (sustainability phase). Questionnaires will be given at baseline, 6-month, and 12-month of the intervention to assess fear of hypoglycemia, diabetes knowledge, overall satisfaction of the platform. Participant will also receive 1 question every 6 weeks regarding the frequency of hypoglycemia during the last 3 days. The observational control group will not have access to the platform. We will extract data from the baseline, 6 months and annual registry completion.
Analysis:
Initial analysis will be descriptive and baseline data will be summarized separately for both groups. Baseline continuous data will be reported as means with standard deviations (median and interquartile range if data are skewed). Categorical data will be reported as proportions. Our primary outcome is the difference in mean self-reported hypoglycemia and fear of hypoglycemia score between the 2 groups after 6 months of intervention. The primary outcome will be calculated and compared between the two groups using differences with 95% CI using paired t-test and McNemar test. Analysis will be by intention to treat.
Sample size and pairing:
Every participant in the intervention group will be randomly paired by gender and date of completion of the phase 2 BETTER questionnaire (+/- 1 month) with a participant who answered the second phase of the BETTER registry but who did not respond to the invitation e-mail for the SUPPORT study. We have calculated the number of pairs to be able to detect a 25% reduction in adults given the small but present difference in self-reported hypoglycemia in both age groups. We estimate a 25% reduction in hypoglycemic episodes for a between-group difference of 0.95. Assuming a common standard deviation of 4.5, for a 2-sided alpha=0.05 and 80% power to detect such a difference with sample size calculation for comparing paired differences, we will require 179 pairs of participants in total. Allowing for a up to 35% loss to follow-up, we will require 275 pairs of participants.
Importance of this study:
Once validated, the SUPPORT online training platform for individuals with type 1 diabetes can be a low-cost and easily accessible training to complement regular care and increase knowledge of diabetes-related therapies and technologies.
- Being tested
- SUPPORT online platform for people with type 1 diabetes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SUPPORT online platform for people with type 1 diabetesOther
All participants accepting the SUPPORT study will receive the full intervention for 6 months. Their learning is individualized depending on the way they take their insulin (injection or pump) and the way they measure their blood sugar (finger prick or continuous glucose monitoring).
The training program starts with mandatory module on hypoglycemia. Once completed, participants will unlock all level 1 (out of 3 levels) modules from the 6 categories (medication, blood sugar monitoring, nutrition, physical activity, hypo- and hyperglycemia, health and other situations). The platform contains functionalities such as discussion forum, quizzes, videos, downloadable forms, etc. During the first 6 months, participants will receive a bi-weekly newsletter to inform them about what's new on the platform.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | The intervention group will have immediate access to the SUPPORT platform. Receives: Other: SUPPORT online platform for people with type 1 diabetes |
What is being measured
The primary outcome is the main question the study is designed to answer.
Users' satisfaction of the SUPPORT platform
Online questionnaire- General satisfaction of the SUPPORT platform-8 items
Measured: after 6 months
Secondary outcomes (4)
Users' engagement on the SUPPORT platform
Extracted from Google Analytics: Number of page viewed, time spent on the platform, number of downloaded PDFs, number of forum posts
Measured: baseline to 6 months
Change in the frequency and the fear of hypoglycemia
Self-reported (compared to baseline)
Measured: 6-month, and 12-month
Change in the glycated hemoglobin
Self-reported (compared to baseline)
Measured: at 6 months and 12 months
Knowledge about diabetes self-management
Online questionnaire based on content seen on the SUPPORT platform- 7 items
Measured: at baseline, 6 months and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jan 2020
- Study start5 Feb 2020
- Primary completion19 Mar 2023
- Study completion19 Sep 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Type 1 Diabetes Mellitus With HypoglycemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Participants enrolling in the study have access to the online platform for 12 months (6 months with reminders, 6 months no reminders).
- Masking
- None (open label)
- Enrolment
- 285 participants (actual)
Sponsor and investigators
- Lead sponsor
- McGill University
- Sponsor type
- University, hospital or other
- Collaborators
- Institut de Recherches Cliniques de Montreal, Juvenile Diabetes Research Foundation, Canadian Institutes of Health Research (CIHR)
- Responsible party
- Principal investigator, Anne-Sophie Brazeau, McGill University
- Investigators
- Anne-Sophie Brazeau, PhD, Principal investigator, McGill University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04233138
- Sponsor's protocol ID
- SUPPORT
- Acronym
- SUPPORT
- Status last verified
- Apr 2022
- First submitted
- 15 Jan 2020
- Last updated
- 25 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Xie LF, Housni A, Roy-Fleming A, Bandini A, Delormier T, Costa DD, Brazeau AS. Evaluation of Support, a self-guided online type 1 diabetes self-management education and support web application-a mixed methods study. Digit Health. 2023 Sep 28;9:20552076231204435. doi: 10.1177/20552076231204435. eCollection 2023 Jan-Dec.
PubMed 37780064
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimizing Therapies and Technologies to Reduce Hypoglycemia in Type 1 Diabetes Through the SUPPORT Online Platform for Self-management Education and Support
- ClinicalTrials.gov ID
- NCT04233138
- Acronym / sponsor ID
- SUPPORT / SUPPORT
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 285 participants (actual)
- Lead sponsor
- McGill UniversityUniversity, hospital or other
- Collaborators
- Institut de Recherches Cliniques de Montreal, Juvenile Diabetes Research Foundation, Canadian Institutes of Health Research (CIHR)
- Study start
- 5 Feb 2020 (actual)
- Primary completion
- 19 Mar 2023 (actual)
- Study completion
- 19 Sep 2023 (actual)
- First posted
- 18 Jan 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There are evidences that some healthcare teams are not proposing new therapeutic and technology options that have the potential to reduce hypoglycemia for people with type 1 diabetes. In practice, people living with type 1 diabetes report receiving education related to insulin pumps usage mainly on key functions (how the device works) at initiation and not enough about proactive adjustments (how to optimally use the device) especially on the long-term. In brief, short-term education is technical and product-specific, rather than being based on patients' needs.There is a need to test the efficacy of different programs that may be more suited to patients' needs and desires while offering the opportunity to reduce costs (e.g. web based). Since there is a lack of expertise related to optimal use of new technologies and therapies for people living with type 1 diabetes, we propose to design and test a web-based training (e.g. courses including videos and quizzes) and support (e.g. discussion forum) platform. This will be tested through a registry-based trial.
The overall purpose of this study is to evaluate, among a group of adults living with type 1 diabetes, the SUPPORT online education platform in terms of users' satisfaction, engagement and efficacy to change the fear and the frequency of hypoglycemia.
Detailed description
Design and development of the SUPPORT platform:
The SUPPORT platform was designed based on the Behavior change wheel framework. The research team identified the main barriers in achieving adequate blood glucose management and in the use of an online training platform; then, features (downloadable PDFs, videos, quizzes, etc.) were designed to overcome these barriers. These training modules were developed by a team including two dietitians/certified diabetes educator, a nurse, a psychologist and endocrinologist (all specialized in type 1 diabetes). The content was then reviewed by the committee of patient-partners and clinicians working in type 1 diabetes (one endocrinologist, two residents in endocrinology, two dietitians (1 being a certified diabetes educator) and two nurses (1 being a certified diabetes educator).
Recruitment and intervention:
Recruitment of people with type 1 diabetes will be done via an email sent to the participants who completed phase 2 of the BETTER registry, are 18 years old or older, and agreed to be contacted for other studies. All participants accepting to participate will receive the full intervention for 6 months (access to the platform with bi-weekly newsletters). During the following 6 months, participants will still have access to the platform, but no newsletter will be sent (sustainability phase). Questionnaires will be given at baseline, 6-month, and 12-month of the intervention to assess fear of hypoglycemia, diabetes knowledge, overall satisfaction of the platform. Participant will also receive 1 question every 6 weeks regarding the frequency of hypoglycemia during the last 3 days. The observational control group will not have access to the platform. We will extract data from the baseline, 6 months and annual registry completion.
Analysis:
Initial analysis will be descriptive and baseline data will be summarized separately for both groups. Baseline continuous data will be reported as means with standard deviations (median and interquartile range if data are skewed). Categorical data will be reported as proportions. Our primary outcome is the difference in mean self-reported hypoglycemia and fear of hypoglycemia score between the 2 groups after 6 months of intervention. The primary outcome will be calculated and compared between the two groups using differences with 95% CI using paired t-test and McNemar test. Analysis will be by intention to treat.
Sample size and pairing:
Every participant in the intervention group will be randomly paired by gender and date of completion of the phase 2 BETTER questionnaire (+/- 1 month) with a participant who answered the second phase of the BETTER registry but who did not respond to the invitation e-mail for the SUPPORT study. We have calculated the number of pairs to be able to detect a 25% reduction in adults given the small but present difference in self-reported hypoglycemia in both age groups. We estimate a 25% reduction in hypoglycemic episodes for a between-group difference of 0.95. Assuming a common standard deviation of 4.5, for a 2-sided alpha=0.05 and 80% power to detect such a difference with sample size calculation for comparing paired differences, we will require 179 pairs of participants in total. Allowing for a up to 35% loss to follow-up, we will require 275 pairs of participants.
Importance of this study:
Once validated, the SUPPORT online training platform for individuals with type 1 diabetes can be a low-cost and easily accessible training to complement regular care and increase knowledge of diabetes-related therapies and technologies.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Participants enrolling in the study have access to the online platform for 12 months (6 months with reminders, 6 months no reminders).
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Other: SUPPORT online platform for people with type 1 diabetesThe intervention group will have immediate access to the SUPPORT platform. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- ≥ 18 years old
- Completed phase 2 of the BETTER registry
- Self-reported diagnosis of type 1 diabetes for ≥ 1 year
- Daily use of ≥ 4 injections of insulin or CSII
- Have access to Internet
Key exclusion criteria (2 listed)
- Ongoing pregnancy
- Other illnesses limiting diabetes care or access to the platform (e.g. dementia and blindness)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SUPPORT online platform for people with type 1 diabetesAll participants accepting the SUPPORT study will receive the full intervention for 6 months. Their learning is individualized depending on the way they take their insulin (injection or pump) and the way they measure their blood sugar (finger prick or continuous glucose monitoring). The training program starts with mandatory module on hypoglycemia. Once completed, participants will unlock all level 1 (out of 3 levels) modules from the 6 categories (medication, blood sugar monitoring, nutrition, physical activity, hypo- and hyperglycemia, health and other situations). The platform contains functionalities such as discussion forum, quizzes, videos, downloadable forms, etc. During the first 6 months, participants will receive a bi-weekly newsletter to inform them about what's new on the platform. | Other | Intervention |
Primary outcome
Users' satisfaction of the SUPPORT platform
Time frame: after 6 months
Online questionnaire- General satisfaction of the SUPPORT platform-8 items
4 secondary outcomes
Users' engagement on the SUPPORT platform
Time frame: baseline to 6 months
Change in the frequency and the fear of hypoglycemia
Time frame: 6-month, and 12-month
Change in the glycated hemoglobin
Time frame: at 6 months and 12 months
Knowledge about diabetes self-management
Time frame: at baseline, 6 months and 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2025.
- Derived from this study: PubMed 37780064Xie LF, Housni A, Roy-Fleming A, Bandini A, Delormier T, Costa DD, Brazeau AS. Evaluation of Support, a self-guided online type 1 diabetes self-management education and support web application-a mixed methods study. Digit Health. 2023 Sep 28;9:20552076231204435. doi: 10.1177/20552076231204435. eCollection 2023 Jan-Dec.
Related trials for Type 1 Diabetes Mellitus With Hypoglycemia
Recruiting
Changes in Person-reported Outcomes and Behavior Using the Accu-Chek SmartGuide CGM and Predict App
Diabetes (DM), Diabetes Mellitus
Not yet recruitingPhase 1/2
Study of the Safety and Efficacy of Pancreatic Endocrine Cells in Adult Patients With Type 1 Diabetes
Diabete Mellitus, Diabete Type 1
RecruitingPhase 1/2
Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes
Diabetes Mellitus, Type 1
Active, not recruitingPhase 1/2
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
Type 1 Diabetes Mellitus
RecruitingPhase 3
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anne-Sophie Brazeau, PhD principal investigator
McGill University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SUPPORT online platform for people with type 1 diabetes in people with Type 1 Diabetes Mellitus With Hypoglycemia, run by McGill University at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Users' satisfaction of the SUPPORT platform (time frame: after 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04233138, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2025.